LexDanaLexDanabeta
Inventor

GRAHAM BEATON

Inventor
US

Overview

10→
Patents
2022–2025
Patent span
Human necessities
Primary field (CPC A)

Patents· 10 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes30%
C07DHeterocyclic compounds27%
A61LMethods or apparatus for sterilising materials or objects in general7%
C07CAcyclic or carbocyclic compounds3%
PatentTitleYear
12,357,570Chemoembolization agents202512,234,224Pyrimidine and pyridine amine compounds and usage thereof in disease treatment202512,145,913Inhibition of Olig2 activity202411,866,421Pyrimidine and pyridine amine compounds and usage thereof in disease treatment202411,712,418Chemoembolization agents202311,713,324Gonadotropin-releasing hormone receptor antagonists and methods relating thereto202311,691,951Inhibition of Olig2 activity202311,685,722Inhibition of Olig2 activity202311,427,552Heterocyclic compounds useful in the treatment of disease202211,242,323Inhibition of OLIG2 activity2022

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2022–2024Patents assigned to CURTANA PHARMACEUTICALS INC (4)· patent assignee history
2022–2025Patents assigned to EPIGEN BIOSCIENCES INC (3)· patent assignee history
2022–2025Based in US· patent location history
2023–2025Patents assigned to BRUIN BIOSCIENCES INC (2)· patent assignee history
2023–2025Patents assigned to UNIV CALIFORNIA (2)· patent assignee history
2023Patents assigned to NEUROCRINE BIOSCIENCES INC (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CURTANA PHARMACEUTICALS INC42022–2024
EPIGEN BIOSCIENCES INC32022–2025
BRUIN BIOSCIENCES INC22023–2025
UNIV CALIFORNIA22023–2025
NEUROCRINE BIOSCIENCES INC12023
Locations
LocationPatentsSpan
US102022–2025